Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Notarfranchi

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|September 9, 2017
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesFederica Costa, Rosanna Vescovini, Marina Bolzoni, et al.
Oncoimmunology|September 15, 2022
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral responsePaola Storti, Valentina Marchica, Rosanna Vescovini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple MyelomaMarta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|September 9, 2017
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesFederica Costa, Rosanna Vescovini, Marina Bolzoni, et al.
Oncoimmunology|September 15, 2022
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral responsePaola Storti, Valentina Marchica, Rosanna Vescovini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple MyelomaMarta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Pageof 2